Filing Analysis
Boundless Bio, Inc. reported the results of its annual meeting of stockholders held on June 15, 2026. The stockholders elected Class II directors and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year.
📋 Key Facts
- Annual meeting of stockholders held on June 15, 2026.
- James Christensen, Ph.D. and Jennifer Lew were elected as Class II directors to serve until the 2029 annual meeting.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 2 (Auditor ratification) received 15,376,973 votes in favor and 127,747 votes against.
Boundless Bio, Inc. announced its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release attached as an exhibit to the filing.
📋 Key Facts
- The company reported financial results for the fiscal quarter ended March 31, 2026.
- The filing was made on May 8, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The financial information in the press release (Exhibit 99.1) is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Boundless Bio is an emerging growth company as defined in Rule 405.
Boundless Bio, Inc. entered into an agreement to terminate its 80,168 square foot laboratory and office lease in San Diego effective May 31, 2026, more than eight years ahead of the original 2034 expiration date. The company will incur a $10.0 million termination payment and forfeit a $0.5 million security deposit to exit the agreement.
🚩 Red Flags
- Significant cash outflow of $10.5 million for a non-operational expense.
- Abrupt exit from a long-term facility commitment eight years early, suggesting a major pivot or downsizing.
- Forfeiture of the entire security deposit.
📋 Key Facts
- Lease termination for 80,168 rentable square feet at 10955 Alexandria Way, San Diego.
- The lease was originally scheduled to expire on October 31, 2034.
- The company must pay a $10.0 million lease modification payment.
- The landlord will retain the full $0.5 million security deposit.
- The termination was contingent on the landlord securing a new tenant, a condition that has been satisfied.
- The effective termination date is May 31, 2026.
Boundless Bio, Inc. reported its Q4 and full-year 2025 financial results and announced the resignation of board member Dr. Christine Brennan. Dr. Brennan's departure is effective March 3, 2026, and is not due to any disagreement with the company.
📋 Key Facts
- Financial results for the fourth quarter and full year ended December 31, 2025, were released on March 9, 2026.
- Dr. Christine Brennan resigned from the Board of Directors effective March 3, 2026.
- The resignation is attributed to Dr. Brennan assuming a new role at Johnson & Johnson Development Corporation.
- The company stated there were no disagreements regarding operations, policies, or practices.